Grace Therapeutics
GRCE
23 hedge funds and large institutions have $15M invested in Grace Therapeutics in 2025 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 4 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
36% more capital invested
Capital invested by funds: $11M → $15M (+$3.96M)
15% more funds holding
Funds holding: 20 → 23 (+3)
1.17% more ownership
Funds ownership: 26.8% → 27.97% (+1.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cerity Partners
New York
|
+$1.34M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$926K |
| 3 |
Renaissance Technologies
New York
|
+$144K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$96.1K |
| 5 |
Morgan Stanley
New York
|
+$75K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$628K |
| 2 |
MFA
Millington Financial Advisors
Naperville,
Illinois
|
-$59.7K |
| 3 |
SWM
SeaCrest Wealth Management
Purchase,
New York
|
-$42K |
| 4 |
Citigroup
New York
|
-$8.19K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$89 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Citigroup
New York
| – | -$8.19K | -2,757 | Closed |
|
|
MI
27
Motiv8 Investments
Port St. Lucie,
Florida
| – | +$64 | +20 | New |
|
GRCE Hedge Fund Activity: Q4 2025 in Review
23 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q4 2025, worth a combined $15M — up 36% from $11M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new GRCE positions and 4 closed out — a net gain of 3 holders — while 6 added to existing stakes and 1 trimmed.
The largest buyer was Cerity Partners, opening a new position worth an estimated $1.34M. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $628K sold.
- 23 institutional investors held Grace Therapeutics (GRCE) as of Q4 2025, up from 20 in Q3 2025.
- Funds reported $15M of Grace Therapeutics stock for Q4 2025, up 36% quarter-over-quarter.
- 7 funds opened new Grace Therapeutics positions in Q4 2025 and 4 closed out, a net change of +3 holders.
- The largest Grace Therapeutics buyer in Q4 2025 was Cerity Partners, an estimated $1.34M added.
- The largest Grace Therapeutics seller in Q4 2025 was Stonepine Capital Management, an estimated $628K sold.
Based on aggregated 13F filings for Q4 2025.